Sodium salicylate

What it is

Sodium salicylate is the sodium salt of salicylic acid, the oldest of the salicylate drugs and the one from which aspirin was derived. In the current US market it is hard to find as a single-ingredient human medicine: a search of DailyMed in October 2026 returned sodium salicylate almost entirely as veterinary solutions and powders, and as the analgesic half of over-the-counter urinary products combined with the antibacterial methenamine, such as Cystex, where each tablet holds methenamine 162 mg and sodium salicylate 162.5 mg and is labelled as an NSAID. Like magnesium salicylate it is a non-acetylated salicylate. Each Cystex tablet also carries sodium 24.4 mg, and the label tells people on a sodium-restricted diet to ask a doctor before use.

What the research says

Sodium salicylate is a weak cyclo-oxygenase inhibitor and, in the respiratory-challenge literature, it is described as hardly active on cyclo-oxygenase at all. Its only current labelled human use in the US is as the pain-relieving component of a methenamine combination for the pain and burning of urination, which is a regulatory position rather than a trial result: we found no placebo-controlled trial of sodium salicylate for that use. The firmest things the literature says about it are negative or cautionary: it does not inhibit platelets the way aspirin does, so it cannot stand in for aspirin's cardiovascular trials; it carries the salicylate harms including stomach bleeding, Reye's syndrome in children and teenagers, tinnitus and hearing loss, and salicylate poisoning; and its sodium content matters, because a very large primary-care case-control study found sodium-containing formulations of drugs were associated with more cardiovascular events than the same drugs in non-sodium form.

Evidence grade: Limited evidence.

How it works

Drug class: Non-acetylated salicylate; non-steroidal anti-inflammatory drug (NSAID)

Sodium salicylate dissolves to give the salicylate anion plus sodium. The salicylate anion weakly damps prostaglandin production through the cyclo-oxygenase enzymes, which is how it relieves pain. Its cyclo-oxygenase effect is weak enough that researchers studying aspirin-intolerant asthma describe sodium salicylate as hardly active on cyclo-oxygenase and well tolerated by patients in whom aspirin triggers attacks. The sodium that comes with it is pharmacologically relevant in its own right. (Source 1)

What it is used for

• This is the labelled use of the over-the-counter combination product, which pairs sodium salicylate as an analgesic with methenamine as an antibacterial. It is a regulatory position: we found no placebo-controlled trial of sodium salicylate for urinary pain, and the label itself limits use to three days and says the product is not intended to replace a doctor's care. Evidence: unknown. (Source 2)
• Sodium salicylate was the original antirheumatic salicylate and is still used this way outside the US, but in the US there is no current single-ingredient human label, and we found no modern randomised trial of it. The nearest contemporary outcome evidence for a non-acetylated salicylate is from salsalate, a different salicylate prodrug, and should not be read as sodium salicylate data. Evidence: limited. (Source 3)
• Researchers in this field describe sodium salicylate as well tolerated by aspirin-intolerant patients because it barely inhibits cyclo-oxygenase, and a blinded crossover study found pre-treatment with a related non-acetylated salicylate blunted aspirin-induced reactions. But a blinded challenge study of a different non-acetylated salicylate still produced reactions in 2 of 10 aspirin-sensitive asthmatic patients, so tolerance is not guaranteed. Evidence: limited. (Source 1)
• Non-acetylated salicylates do not irreversibly acetylate platelet cyclo-oxygenase-1, the step held to explain aspirin's cardiovascular benefit, and platelet-function studies of non-acetylated salicylates show no inhibition of aggregation. Aspirin's outcome trials are not evidence for sodium salicylate. Evidence: not-supported. (Source 4)

Interactions

• A sodium-restricted diet, and sodium generally (label): Each tablet carries sodium 24.4 mg, so six tablets a day add about 146 mg of sodium. The label names a sodium-restricted diet as a reason to ask a doctor before use, alongside high blood pressure, heart disease, liver cirrhosis and kidney disease. (Source 5)
• Alcohol (label): Three or more alcoholic drinks a day while using the product is named on the label as raising the chance of stomach bleeding. (Source 2)
• Aspirin and other NSAIDs (label): Taking another NSAID at the same time raises the stomach-bleeding chance; the label asks for a pharmacist or doctor check for any other NSAID, prescription or not. (Source 5)
• Anticoagulants, steroids, and drugs for diabetes, gout or arthritis (label): The label groups these together as reasons to ask a doctor or pharmacist before use. (Source 5)
• Aspirin, in people whose asthma aspirin triggers (clinical trial): Salicylate pre-treatment interacts with aspirin at the cyclo-oxygenase site in the airway and partly blunted aspirin-induced bronchial and nasal reactions in a blinded crossover study. Studied with choline magnesium trisalicylate rather than sodium salicylate. Limit: The salicylate given in this study was choline magnesium trisalicylate, not sodium salicylate, and only nine aspirin-intolerant patients took part. The authors call the effect moderate protection and say the mechanism is unknown. (Source 1)
• Other sodium-containing medicines, including effervescent and soluble formulations (case reports): The sodium that comes with the salt adds to the sodium in other soluble or effervescent medicines. In a 1.29 million patient primary-care study, sodium-containing formulations were associated with higher odds of cardiovascular events than the same drugs in standard form, most strikingly for hypertension. (Source 6)

Stopping it

• We found no withdrawal syndrome, rebound-symptom or tapering literature for sodium salicylate. The label treats stopping as a time limit and a set of stop rules rather than a taper: it limits use to three days unless a doctor directs, and tells the user to stop and ask a doctor if ringing in the ears occurs or if signs of stomach bleeding appear. (Source 7)
• In the poisoning setting, serum salicylate can rise again after intravenous sodium bicarbonate is stopped, but in a 377-case review this happened in only 2.1% and the one patient with recurrent symptoms had tinnitus. (Source 8)

What goes wrong

Sodium-containing formulations of drugs were associated with more cardiovascular events than non-sodium formulations of the same drugs in a 1.29 million patient primary-care database, which is the best available evidence that the sodium a salicylate salt carries is not inert. (Source 9)

• Case-control study, Low certainty.
• Size: 1,292,337 patients in the cohort; 61,072 patients with an incident cardiovascular event matched to controls.
• Who: UK primary care patients aged 18 or over prescribed at least two prescriptions of sodium-containing or matched standard formulations, 1987 to 2010.
• How long: Mean follow-up 7.23 years; median 3.92 years from first prescription to first event.
• Result: Adjusted odds ratio for the composite of incident non-fatal myocardial infarction, incident non-fatal stroke or vascular death was 1.16 (95% CI 1.12 to 1.21); non-fatal stroke 1.22 (1.16 to 1.29); all cause mortality 1.28 (1.23 to 1.33); hypertension 7.18 (6.74 to 7.65); heart failure 0.98 (0.93 to 1.04); non-fatal myocardial infarction 0.94 (0.88 to 1.00)
• Funding: not stated.

Limit of this finding: Read the whole row, not the headline. The composite odds ratio of 1.16 sits beside secondary results that point the other way or nowhere: non-fatal myocardial infarction 0.94 (0.88 to 1.00) and vascular death 0.70 (0.31 to 1.59), while the hypertension odds ratio of 7.18 is so far from the rest that how the exposed group was defined is doing much of the work. This is an observational database study, so it shows an association between sodium-containing formulations and events, not that the sodium caused them, and it studied sodium-containing medicines in general rather than sodium salicylate.

For the primary endpoint of incident non-fatal myocardial infarction, incident non-fatal stroke, or vascular death the adjusted odds ratio for exposure to sodium-containing drugs was 1.16 (95% confidence interval 1.12 to 1.21).

The authors of that study recommended sodium-containing formulations be prescribed with caution; because it is observational, the association cannot be read as proof that the sodium caused the events. (Source 6)

• Case-control study, Low certainty.
• Size: 61,072 matched case-control pairs.
• Who: UK primary care.
• How long: Mean follow-up 7.23 years.
• Result: The paper reports an association, not a causal effect; the hypertension odds ratio of 7.18 is large enough that confounding by indication and by effervescent-formulation prescribing patterns must be considered.
• Funding: not stated.

Sodium-containing formulations should be prescribed with caution only if the perceived benefits outweigh these risks.

The sodium salicylate combination label carries the full NSAID stomach-bleeding warning and names a sodium-restricted diet as a reason to ask a doctor first. (Source 2)

• Official position, Certainty not rated.
• Size: Not applicable (label warning)
• Who: Anyone taking the product.
• How long: Not applicable.
• Result: No rates given; the label names age 60 or older, stomach ulcers or bleeding problems, anticoagulant or steroid use, other NSAIDs, three or more alcoholic drinks a day, and taking more or longer than directed as factors raising the chance.
• Funding: not stated (manufacturer label)

Stomach bleeding warning:This product contains a nonsteroidal anti-inflammatory drug (NSAID), which may cause stomach bleeding. The chance is higher if you

The same label carries the Reye's syndrome restriction for children and teenagers with chicken pox or flu-like symptoms, and the epidemiology behind that warning is a strong case-control association. (Source 10)

• Case-control study, Low certainty.
• Size: 24 case subjects and 48 matched controls.
• Who: Children with Reye's syndrome and matched controls.
• How long: Case-control with bias-control procedures.
• Result: 88% of cases versus 17% of controls had received aspirin before onset; matched odds ratio 35 (95% CI 4.2 to 288); the authors report the association could not be attributed to five potential sources of bias.
• Funding: not stated.

Limit of this finding: The abstract prints 'Eight-eight percent of case subjects' where it plainly means eighty-eight percent; the typo is the journal's own and is kept here unaltered. The figures are internally consistent either way (21 of 24 cases is 87.5 per cent). The exposure studied was aspirin, not sodium salicylate.

Further analyses demonstrated that the association could not be attributed to the five potential sources of bias.

Salicylate is directly ototoxic at high exposure, producing tinnitus and reversible sensory hearing loss, and the label instructs the user to stop if ringing in the ears occurs. (Source 11)

• Expert review, not systematic, Low certainty.
• Size: Not applicable (review of animal and human work)
• Who: Animal models plus human salicylate and aspirin exposure.
• How long: Acute and chronic dosing studies.
• Result: No incidence figures; chronic dosing produced temporary enhancement of DPOAE amplitudes and up-regulation of prestin, and cultured cochlea studies showed an upsurge of superoxide radicals leading to apoptosis of spiral ganglion neurons.
• Funding: not stated.

Despite salicylate's antioxidant properties, cultured cochlea studies indicate it also impairs spiral ganglion neurons (SGNs) by paradoxically causing an upsurge of superoxide radicals leading to apoptosis.

Acute salicylate poisoning sent one in five adult emergency department presentations in a prospective cohort to a severe outcome, and the initial salicylate level alone did not identify them. (Source 12)

• Cohort study, Low certainty.
• Size: 48 patients met inclusion criteria out of 1,997 overdoses screened.
• Who: Adults with confirmed salicylate ingestion at two urban university teaching hospitals.
• How long: Prospective cohort 2009 to 2013.
• Result: 20.8% classified as severe outcome (acidemia pH <7.3 or bicarbonate <16 mEq/L, haemodialysis and/or death); lactate cutpoint 2.25 mmol/L gave 78% sensitivity and 67% specificity.
• Funding: not stated.

Patient characteristics were 43.8% male, median age 32 (range 18-87), mean initial salicylate concentration 28.1 mg/dL (SD 26.6), and 20.8% classified as severe outcome.

A non-acetylated salicylate can still cross-react in aspirin-sensitive asthma, so the tolerance claim is probabilistic rather than absolute. (Source 13)

• Randomized trial, Very low certainty.
• Size: 10 aspirin-sensitive patients with asthma.
• Who: Adults with confirmed aspirin-sensitive asthma.
• How long: Double-blind placebo-controlled oral challenges with confirmatory re-challenge.
• Result: 2 of 10 patients developed respiratory reactions to 2 g salsalate, reproduced on repeat challenge; reactions mild and treated with beta-2 agonists.
• Funding: not stated (two authors affiliated to the salsalate manufacturer per the author list)

Limit of this finding: This was a challenge study in ten patients, and two of them reacted. Two out of ten cannot pin down how common cross-reaction is. The drug challenged was salsalate, not sodium salicylate.

We conclude that salsalate, a weak inhibitor of cyclooxygenase in vitro, is less likely than ASA to induce asthma in known ASA-sensitive patients with asthma but may occasionally cross-react in these patients.

The salsalate trialists' own summary of that renal signal was explicit. (Source 14)

• Randomized trial, Moderate certainty.
• Size: 192 persons without diabetes at baseline.
• Who: Overweight statin-treated adults with stable coronary heart disease.
• How long: 30 months.
• Result: No separate rate given in the conclusion; the albuminuria increase reported was 16.7 mcg/mg (95% CI 6.4 to 27.1, P<0.001)
• Funding: not stated in the abstract.

Limit of this finding: The conclusion's phrase 'may decrease risk of incident type 2 diabetes' is an extrapolation: no one in this trial was followed for a diabetes diagnosis, so no such risk was measured. The second half of the conclusion, that renal safety may limit clinical utility, is the load-bearing part and must travel with the first. The paper prints 'albuminurea' for albuminuria; that spelling is the source's own.

Salsalate may inform new therapeutic approaches for diabetes prevention, but renal safety may limit clinical utility.

Upper gastrointestinal complication risk differs several-fold between individual NSAIDs and rises 2 to 3 times with high daily doses; the meta-analysis could not place any salicylate salt on that scale. (Source 15)

• Meta-analysis, Low certainty.
• Size: 28 studies met the meta-analysis inclusion criteria.
• Who: Users of individual NSAIDs versus non-users in cohort and case-control studies.
• How long: Studies published 1980 to 2011.
• Result: RRs for high daily doses were 2-3 times higher than for low daily doses; individual drug estimates ranged from 1.43 to 18.45.
• Funding: European Community's Seventh Framework Programme (SOS project)

RRs for the use of high daily doses of NSAIDs versus non-use were 2-3 times higher than those associated with low daily doses.

What the evidence supports

The only current US human label we found for sodium salicylate is as the analgesic component of an over-the-counter methenamine combination for urinary pain, and that label limits use to a three-day period unless a doctor directs otherwise. (Source 7)

• Official position, Certainty not rated.
• Size: One marketed combination product label.
• Who: Adults and children 12 years and over; children under 12 told to ask a doctor.
• How long: Label limits use to a 3 day period unless a doctor directs.
• Result: Label states each tablet contains methenamine 162 mg and sodium salicylate 162.5 mg (NSAID), labelled purpose 'Analgesic (pain reliever)', dose 2 tablets with a full glass of water 3 times a day for adults and children 12 and over, children under 12 to ask a doctor, and no more than a 3 day period unless a doctor directs. The per-tablet strengths and the labelled purpose are in the Active ingredients and Purpose sections, recorded under cystex-label-2025.
• Funding: not stated (manufacturer label)

Do not use for more than a 3 day period unless directed by a doctor.

Sodium salicylate is described in the aspirin-intolerant asthma literature as hardly active on cyclo-oxygenase by itself and well tolerated by patients in whom aspirin precipitates asthma attacks. (Source 1)

• Randomized trial, Very low certainty.
• Size: 9 aspirin-intolerant patients.
• Who: Adults with aspirin-intolerant asthma.
• How long: Choline magnesium trisalicylate 3000 mg daily for 3 days before aspirin challenge, double-blind placebo-controlled randomised crossover.
• Result: Maximal decreases in FEV1 and reaction intensity indexes were significantly lower after the non-acetylated salicylate pre-treatment than after placebo (P less than 0.02 and P less than 0.002 respectively); nasal symptoms were attenuated in 3 of 5 patients.
• Funding: not stated.

Limit of this finding: Nine patients, and the sentence quoted is the authors' framing of what was already known rather than a result of this study. The protective effect they measured was moderate and used choline magnesium trisalicylate. 'Well tolerated by these patients' is a statement about a small, selected group, not a safety guarantee for anyone whose asthma aspirin triggers.

Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.

What the evidence does not support

Non-acetylated salicylates did not inhibit platelet aggregation at a salicylate exposure matched to aspirin, so sodium salicylate cannot be assumed to carry aspirin's antiplatelet effect. (Source 16)

• Randomized trial, Low certainty.
• Size: 12 healthy volunteers.
• Who: Healthy adult volunteers.
• How long: Two single doses 10 days apart, double blind, random order.
• Result: Aspirin 652 mg inhibited collagen-induced (p<0.005), arachidonic-acid-induced (p<0.01) and spontaneous (p<0.01) platelet aggregation; choline magnesium trisalicylate 655 mg did not.
• Funding: not stated.

We suggest that CMT may have therapeutic potential as an alternative to aspirin when inhibition of platelet aggregation can induce bleeding complications.

The same absence of platelet effect was found for salsalate, including in people with haemophilia A, which supports the class statement rather than the individual salt. (Source 17)

• Randomized trial, Very low certainty.
• Size: 12 healthy subjects and 9 patients with haemophilia A.
• Who: Healthy adults and men with haemophilia A.
• How long: Not stated in the abstract.
• Result: No bleeding time prolongation and no effect on ADP or collagen induced platelet aggregation in platelet rich plasma in the haemophilia A patients.
• Funding: not stated.

Limit of this finding: The source's first sentence prints 'Salsalate in a non-acetylated salicylate' where it means 'is'. That is the journal record's own typo, kept here unaltered. It does not affect the result. The drug studied was salsalate, not sodium salicylate, and the outcomes were platelet laboratory tests, not bleeding events.

The patients with hemophilia A showed no bleeding time prolongation nor an effect on ADP or collagen induced platelet aggregation in platelet rich plasma.

The pharmacological reason aspirin's cardiovascular outcome trials do not transfer to sodium salicylate is that aspirin works by acetylating platelet cyclo-oxygenase-1, which a non-acetylated salicylate cannot do. (Source 4)

• Expert review, not systematic, Certainty not rated.
• Size: Not applicable (mechanistic review)
• Who: Not applicable.
• How long: Not applicable.
• Result: No effect estimate; the review states the COX-1 inactivation effect is necessary and sufficient to explain aspirin's unique effectiveness among COX-1 inhibitors.
• Funding: not stated.

Limit of this finding: This is a narrative review, and the sentence quoted is the reviewers' account of the accepted mechanism rather than a new measurement. It is used only for why aspirin's cardiovascular trials cannot be read across to a non-acetylated salicylate.

This effect is necessary and sufficient to explain aspirin's unique (among other COX-1 inhibitors) effectiveness in preventing atherothrombosis, as well as its shared (with other antiplatelet agents) bleeding liability.

Where the evidence is mixed

A 30-month placebo-controlled trial of the non-acetylated salicylate salsalate did lower glucose measures, but it also increased albuminuria, and the trialists said renal safety may limit its usefulness. This is the closest long-term outcome evidence for a non-acetylated salicylate, and it is not sodium salicylate. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 192 persons without diabetes at baseline, pre-specified secondary analysis of TINSAL-CVD.
• Who: Overweight, mostly Caucasian men, age 60 plus or minus 7 years, statin-treated stable coronary heart disease, BMI 31.4 plus or minus 3.0.
• How long: 30 months.
• Result: Fasting glucose -5.70 mg/dL (95% CI -7.44 to -3.97, P<0.001); HbA1c -0.11% (95% CI -0.210 to -0.002%, P=0.046); glycated serum protein -81.8 mcg/mL (95% CI -93.7 to -69.9, P<0.001); albuminuria +16.7 mcg/mg (95% CI 6.4 to 27.1, P<0.001); white cell count -0.7x10^3/mcL.
• Funding: not stated in the abstract; TINSAL-CVD was an investigator-led multi-centre trial.

Limit of this finding: Two things about this trial are easy to misread. It is a pre-specified secondary analysis of a cardiovascular trial, run in 192 people who did not have diabetes at the start, so it is not a primary trial of blood-sugar control. And the drug was salsalate, not sodium salicylate. The paper also contradicts itself on who was studied: its title says 'overweight persons' while its conclusion says 'obese persons', with a mean body mass index of 31.4. The albuminuria rise reported alongside the glucose fall is part of the same result and should not be separated from it.

Salsalate lowered total white blood cell counts (mean difference -0.7x103 /μL, 95%CI: -1.0 to -0.4 x103 /μL, P<0.001) and increased adiponectin (mean difference 1.8 μg/mL, 95%CI: 0.9 to 2.6 μg/mL, P<0.001) and albuminurea (16.7 μg/mg, 95%CI: 6.4 to 27.1 μg/mg, P<0.001) compared to placebo, consistent with previous results for patients with type 2 diabetes taking salsalate for shorter times.

Where the research disagrees

Whether sodium salicylate and other non-acetylated salicylates are a safe substitute in people whose asthma is triggered by aspirin

• Nizankowska, Szczeklik and colleagues, Krakow, Double-blind placebo-controlled randomised crossover challenge study in 9 aspirin-intolerant patients: Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients. (Source 1)
• Stevenson and colleagues, Scripps Clinic, Double-blind placebo-controlled oral challenge with confirmatory re-challenge in 10 aspirin-sensitive asthmatic patients: We conclude that salsalate, a weak inhibitor of cyclooxygenase in vitro, is less likely than ASA to induce asthma in known ASA-sensitive patients with asthma but may occasionally cross-react in these patients. (Source 13)

How much

• Reference intake: There is no prescriber-set dose for sodium salicylate in the current US market because there is no single-ingredient human product; the dose is set by the combination product's over-the-counter label. The Cystex label, SPL effective 2025-12-27, states: 'take 2 tablets with a full glass of water 3 times a day. Drink plenty of fluids.' for adults and children 12 years and over, with children under 12 told to ask a doctor. Recorded as the label's position, not a recommendation. (Source 7)
• Upper limit: The label's own ceiling is 2 tablets three times a day, each tablet containing sodium salicylate 162.5 mg and sodium 24.4 mg, for no more than a 3 day period unless a doctor directs. No tolerable upper intake level exists because this is a drug. The label separately tells people on a sodium-restricted diet to ask a doctor before use. (Source 7)
• Studied: We found no placebo-controlled trial that gave people sodium salicylate, so no studied dose can be reported for this salt. In the aspirin-intolerant asthma crossover study that described sodium salicylate as hardly active on cyclo-oxygenase, the salicylate actually dosed was choline magnesium trisalicylate at 3000 mg daily for 3 days. (Source 1)
• Studied: The longest placebo-controlled trial of any non-acetylated salicylate we found ran for 30 months using salsalate, not sodium salicylate, in 192 overweight statin-treated adults. (Source 3)

A common belief, and what the research shows

The belief: Sodium salicylate is just aspirin's milder parent, so it does the same job with less risk.

What the research shows: It is the parent compound, but the acetyl group aspirin gained is not cosmetic. Aspirin's cardiovascular benefit is attributed to irreversible acetylation of platelet cyclo-oxygenase-1, described as 'necessary and sufficient to explain aspirin's unique (among other COX-1 inhibitors) effectiveness in preventing atherothrombosis, as well as its shared (with other antiplatelet agents) bleeding liability'. Non-acetylated salicylates do not do this. Meanwhile the risks sodium salicylate does carry are real and labelled: the product label states 'Stomach bleeding warning:This product contains a nonsteroidal anti-inflammatory drug (NSAID), which may cause stomach bleeding. The chance is higher if you', and it carries a sodium load that a very large primary-care study links to more cardiovascular events for sodium-containing formulations generally.

Questions and answers

What is it?

Sodium salicylate is the sodium salt of salicylic acid, the original salicylate drug from which aspirin was made. In the current US market it appears mainly in veterinary products and in over-the-counter urinary pain tablets combined with the antibacterial methenamine, where each tablet holds methenamine 162 mg and sodium salicylate 162.5 mg and is labelled as a non-steroidal anti-inflammatory drug. It is a non-acetylated salicylate, so it lacks aspirin's acetyl group. (Source 2)

What does it do in the body?

It splits into salicylate and sodium. The salicylate weakly damps prostaglandin production through cyclo-oxygenase, which relieves pain; researchers working on aspirin-triggered asthma describe sodium salicylate as hardly active on cyclo-oxygenase by itself, which is why it tends to be tolerated by patients in whom aspirin precipitates attacks. The sodium is not inert: it adds to the body's sodium load. (Source 1)

Is it good or bad for you?

Context decides. For a few days of urinary discomfort in a healthy adult the label treats it as acceptable, though we found no placebo-controlled trial of that use. It becomes a problem for children and teenagers with chicken pox or flu-like symptoms, because of Reye's syndrome; for people on a sodium-restricted diet, with high blood pressure, heart disease, liver cirrhosis or kidney disease; for anyone with a bleeding or ulcer history or on an anticoagulant; and for anyone allergic to salicylates. The label also says not to use it in the last three months of pregnancy unless a doctor directs. (Source 7)

How do you get more of it?

There is no reason to seek more of it, and no dietary route. It is a manufactured drug, available in the US chiefly inside combination urinary tablets whose labelled regimen is 2 tablets with a full glass of water three times a day for adults and children 12 and over, for no more than three days unless a doctor directs. We record that as the label's position rather than advice. (Source 7)

If it is harmful, what reduces it?

Stopping it is what clears it; no withdrawal syndrome is described in the literature we searched. In overdose, clinicians raise urine pH with intravenous sodium bicarbonate to speed excretion, and a review of 377 cases found salicylate rose again after that infusion stopped in 2.1%, with symptoms usually absent or mild. (Source 18)

Why might someone be low in it or missing it?

Nobody is deficient in sodium salicylate; the body neither needs nor makes it, so someone simply does not have it unless they have taken it. The useful version of the question is who should not have it, and the label answers: not anyone allergic to salicylates, and children under 12 should ask a doctor. (Source 5)

Which whole foods contain it or feed it?

No whole food contains sodium salicylate as such. Salicylates occur naturally in many plant foods as salicylic acid and its esters, but the sodium salt sold as a medicine is manufactured, and the product label lists it alongside pharmaceutical excipients only. Sodium salicylate also appears in veterinary drinking-water preparations, which is a different market and not a food source for people. (Source 7)

What happens if you do not have it?

Nothing: there is no deficiency state and no consequence of never taking it. Someone not taking it simply forgoes whatever analgesia it gives, and that has not been quantified against placebo in any trial we found for this salt. The combination label itself is careful to say the product is not a substitute for medical care. (Source 19)

How can you test for it?

There is no test for sodium salicylate as such. Laboratories measure the serum salicylate concentration, the standard test when poisoning is suspected. Its reliability for predicting how a patient will do is poor: in a prospective cohort of 48 adult salicylate overdoses, the initial salicylate concentration alone had no association with severe outcome once age, respiratory rate and lactate were taken into account. (Source 12)

References

1. Clinical and Experimental Allergy. Salicylate pre-treatment attenuates intensity of bronchial and nasal symptoms precipitated by aspirin in aspirin-intolerant patients. 1990. PMID 2083404, DOI 10.1111/j.1365-2222.1990.tb02703.x. Read the source
2. DailyMed (US National Library of Medicine), label of Clarion Brands, LLC product. Cystex (methenamine 162 mg and sodium salicylate 162.5 mg) - Active ingredients (in each tablet), Purpose, Use and Warnings sections of the OTC Drug Facts label, in document order; Active ingredients, Purpose and Warnings carry their own heading in the SPL and are printed under it here, while 'Use' has no heading element and is the styled lead-in the label prints inside the indications section's own text; the label's own footnote marker on '(NSAID)' and its footnote line are kept, and the missing spaces after the colons in "Reye's syndrome:" and 'Stomach bleeding warning:' and the leader dots in the Purpose lines are the label's own (SPL effective 2025-12-27). 2025. Read the source
3. Diabetes, Obesity & Metabolism. Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statin-treated cardiovascular disease: A 30-month randomized placebo-controlled trial (Results section of the abstract). 2017. PMID 28295931, DOI 10.1111/dom.12940. Read the source
4. Journal of the American College of Cardiology. The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. 2015. PMID 26139061, DOI 10.1016/j.jacc.2015.05.012. Read the source
5. DailyMed (US National Library of Medicine), label of Clarion Brands, LLC product. Cystex (methenamine 162 mg and sodium salicylate 162.5 mg) - Do not use, Ask a doctor before use if you have, Ask a doctor or pharmacist before use if you are, When using this product and Stop use and ask a doctor if sections of the OTC Drug Facts label, each section under its own heading exactly as the label prints it, in document order; the four signs of stomach bleeding are a nested sub-list in the SPL and are kept one to a line (SPL effective 2025-12-27). 2025. Read the source
6. BMJ. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study (Conclusions section of the abstract, which is two sentences). 2013. PMID 24284017, DOI 10.1136/bmj.f6954. Read the source
7. DailyMed (US National Library of Medicine), label of Clarion Brands, LLC product. Cystex (methenamine 162 mg and sodium salicylate 162.5 mg) - pregnancy and breast-feeding warning, keep-out-of-reach-of-children warning, Directions, Other information, Inactive ingredients and Questions or comments? sections of the OTC Drug Facts label, in document order; Directions, Other information, Inactive ingredients and Questions or comments? carry their own heading in the SPL and are printed under it here, while the pregnancy and keep-out-of-reach sections carry no heading element and are printed as the continuous sentences the label prints; 'hypromellose ,' with its space before the comma, the missing space in 'children.In case', and 'triethyl titanium dioxide' (which is not a real excipient and looks like a typesetting collision in the SPL) are all the label's own and are kept unaltered (SPL effective 2025-12-27). 2025. Read the source
8. Clinical Toxicology. Incidence of rebound salicylate toxicity following cessation of urine alkalinization (Results section of the abstract). 2023. PMID 37427892, DOI 10.1080/15563650.2023.2227998. Read the source
9. BMJ. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study (Results section of the abstract). 2013. PMID 24284017, DOI 10.1136/bmj.f6954. Read the source
10. JAMA. New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. 1989. PMID 2704111, DOI 10.1001/jama.1989.03420170061031. Read the source
11. Acta Otorhinolaryngologica Italica. Review of salicylate-induced hearing loss, neurotoxicity, tinnitus and neuropathophysiology. 2014. PMID 24843217. Read the source
12. Clinical Toxicology. Acute salicylate poisoning: risk factors for severe outcome (Results section of the abstract). 2017. PMID 28064509, DOI 10.1080/15563650.2016.1271127. Read the source
13. The Journal of Allergy and Clinical Immunology. Salsalate cross-sensitivity in aspirin-sensitive patients with asthma. 1990. PMID 2229840, DOI 10.1016/s0091-6749(05)80179-4. Read the source
14. Diabetes, Obesity & Metabolism. Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statin-treated cardiovascular disease: A 30-month randomized placebo-controlled trial (Conclusions section of the abstract, which is two sentences). 2017. PMID 28295931, DOI 10.1111/dom.12940. Read the source
15. Drug Safety. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project) (the complete Results section of the abstract). 2012. PMID 23137151, DOI 10.2165/11633470-000000000-00000. Read the source
16. Scottish Medical Journal. Therapeutic potential of choline magnesium trisalicylate as an alternative to aspirin for patients with bleeding tendencies. 1987. PMID 3329766, DOI 10.1177/003693308703200603. Read the source
17. Thrombosis Research. Hemostatic effects of salsalate in normal subjects and patients with hemophilia A. 1991. PMID 2020937, DOI 10.1016/0049-3848(91)90165-s. Read the source
18. Clinical Toxicology. Incidence of rebound salicylate toxicity following cessation of urine alkalinization (Conclusions section of the abstract). 2023. PMID 37427892, DOI 10.1080/15563650.2023.2227998. Read the source
19. DailyMed (US National Library of Medicine), label of Clarion Brands, LLC product. Cystex (methenamine 162 mg and sodium salicylate 162.5 mg) - the whole of the first carton panel of the Principal Display Panel (the second carton panel, which repeats the Reye's and stomach-bleeding warnings, is not included) (SPL effective 2025-12-27). 2025. Read the source